# A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

> clinical trial · VERIFIED · 2026-08-14

Status: RECRUITING · Sponsor: ViiV Healthcare · Condition: HIV Infections

- Company: ViiV Healthcare
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT07650916

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.